Login to Your Account



In The Clinic NEWS
Merck & Co. Inc. enrolled the first patient in a global phase III study of letermovir (MK-8228, AIC246), an experimental cytomegalovirus (CMV) antiviral it licensed from Aicuris GmbH.
STOCK SOARS 295 PERCENT
Three months ago, Puma Biotechnology Inc. ran into Wall Street headwinds on findings from its adaptive I-SPY 2 (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis 2) trial of PB272 (neratinib), a pan-HER tyrosine kinase inhibitor, as neoadjuvant therapy in metastatic breast cancer.
'SYNTA STAGE'

With its lead cancer drug unpartnered and a new CEO yet to be chosen, Synta Pharmaceuticals Corp. is advancing the phase II/III AML LI-1 trial to test the chemosensitizing mettle of the heat-shock protein 90 inhibitor ganetespib.

More In The Clinic Headlines

Cast Your Vote

Has biotech’s bubble burst?: